JP2018525447A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525447A5 JP2018525447A5 JP2018530646A JP2018530646A JP2018525447A5 JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5 JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018530646 A JP2018530646 A JP 2018530646A JP 2018525447 A5 JP2018525447 A5 JP 2018525447A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- halogenated
- optionally
- formula
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 39
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 7
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000002971 oxazolyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- -1 heteroaryl halide Chemical class 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 230000001603 reducing effect Effects 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 0 CN(C1=O)C(N)=NC1(c1ccc(*)c(*)c1)C1=C**C(*)=C1 Chemical compound CN(C1=O)C(N)=NC1(c1ccc(*)c(*)c1)C1=C**C(*)=C1 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210945P | 2015-08-27 | 2015-08-27 | |
| US62/210,945 | 2015-08-27 | ||
| PCT/US2016/049271 WO2017035529A1 (en) | 2015-08-27 | 2016-08-29 | Compositions for app-selective bace inhibition and uses therfor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152650A Division JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525447A JP2018525447A (ja) | 2018-09-06 |
| JP2018525447A5 true JP2018525447A5 (cg-RX-API-DMAC7.html) | 2019-08-29 |
Family
ID=58101012
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018530646A Pending JP2018525447A (ja) | 2015-08-27 | 2016-08-29 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
| JP2020152650A Pending JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152650A Pending JP2021001188A (ja) | 2015-08-27 | 2020-09-11 | Ａｐｐ選択的ｂａｃｅ阻害のための組成物およびそのための使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11142505B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3341362B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018525447A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180090778A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108349905A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016311502B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2996542C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017035529A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2956443B1 (en) | 2013-02-12 | 2019-09-25 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| CA2996542C (en) * | 2015-08-27 | 2020-12-29 | Nantneuro, Llc | 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases |
| EP3759079A4 (en) * | 2018-03-01 | 2021-11-17 | The Regents Of The University Of California | AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE |
| US11926599B1 (en) | 2023-10-23 | 2024-03-12 | King Faisal University | 1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU646877B2 (en) | 1990-06-15 | 1994-03-10 | Scios Nova Inc. | Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease |
| CA2101774C (en) | 1991-01-21 | 2011-01-04 | John A. Hardy | Test and model for alzheimer's disease |
| PT620849E (pt) | 1992-01-07 | 2003-11-28 | Elan Pharm Inc | Modelos animais transgenicos para a doenca de alzheimer |
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| AU702293B2 (en) | 1993-10-27 | 1999-02-18 | Athena Neurosciences, Inc. | Transgenic animals harboring APP allele having Swedish mutation |
| US5877399A (en) | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
| EP0871720A2 (en) | 1995-06-07 | 1998-10-21 | Athena Neurosciences, Inc. | Beta-secretase, antibodies to beta-secretase, and assays for detecting beta-secretase inhibition |
| US5744346A (en) | 1995-06-07 | 1998-04-28 | Athena Neurosciences, Inc. | β-secretase |
| AU5002399A (en) | 1998-07-17 | 2000-02-07 | National Broach And Machine Company | Full form roll finishing technique |
| EP1115874B1 (en) | 1998-09-24 | 2009-01-07 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
| AU2005264915A1 (en) * | 2004-06-16 | 2006-01-26 | Wyeth | Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| EP1896448A1 (en) * | 2005-06-30 | 2008-03-12 | Wyeth | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION |
| TW200738683A (en) * | 2005-06-30 | 2007-10-16 | Wyeth Corp | Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation |
| JP2009509957A (ja) * | 2005-09-26 | 2009-03-12 | ワイス | β−セクレターゼ阻害剤としてのアミノ−５−［４−（ジフルオロメトキシ）フェニル］−５−フェニルイミダゾロン化合物 |
| WO2007078813A2 (en) | 2005-12-19 | 2007-07-12 | Wyeth | 2-AMINO-5-PIPERIDINYLIMIDAZOLONE COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION |
| AR065814A1 (es) * | 2007-03-23 | 2009-07-01 | Wyeth Corp | Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados. |
| EP2956443B1 (en) * | 2013-02-12 | 2019-09-25 | Buck Institute For Research On Aging | Hydantoins that modulate bace-mediated app processing |
| US9980769B2 (en) | 2014-04-08 | 2018-05-29 | Ethicon Llc | Methods and devices for controlling motorized surgical devices |
| CA2996542C (en) | 2015-08-27 | 2020-12-29 | Nantneuro, Llc | 5,5'-disubstituted aminohydantoin compounds and compositions useful for inhibition of bace and the treatment of associated diseases |
| WO2019005297A1 (en) | 2017-06-28 | 2019-01-03 | Nantbio, Inc. | BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| EP3759079A4 (en) * | 2018-03-01 | 2021-11-17 | The Regents Of The University Of California | AMYLOID PROTEIN SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER'S DISEASE |
-
2016
- 2016-08-29 CA CA2996542A patent/CA2996542C/en active Active
- 2016-08-29 KR KR1020187008350A patent/KR20180090778A/ko not_active Ceased
- 2016-08-29 AU AU2016311502A patent/AU2016311502B2/en active Active
- 2016-08-29 CN CN201680053449.1A patent/CN108349905A/zh active Pending
- 2016-08-29 CA CA3096896A patent/CA3096896A1/en not_active Abandoned
- 2016-08-29 US US15/755,496 patent/US11142505B2/en active Active
- 2016-08-29 WO PCT/US2016/049271 patent/WO2017035529A1/en not_active Ceased
- 2016-08-29 EP EP16840254.3A patent/EP3341362B1/en active Active
- 2016-08-29 JP JP2018530646A patent/JP2018525447A/ja active Pending
-
2020
- 2020-09-11 JP JP2020152650A patent/JP2021001188A/ja active Pending